Citations

Showing 10 of 108104 citations.

Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma
Jackson, Zachary , Schauner, Robert , Dropulić, Boro, Lima, Marcos de , Giraudo, Maria Florencia , Gupta, Kalpana , Reese, Jane , Hwang, Tae Hyun , Wald, David N., Hong, Changjin , Schauner, Robert , Dropulic, Boro , de Lima, Marcos , Giraudo, Maria Florencia , Hwang, Tae Hyun , Wald, David N , Caimi, Paolo F. , Gupta, Kalpana

Mayo Clinic

Cancer Discovery | May 12, 2022 | Volume: 12 | Issue: 8 | Pages: 1886-1903

10.1158/2159-8290.cd-21-1586 | PMID 35554512 Get It

Abstract Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Nonetheless, many patients receiving CD19 CAR-T cells fail to respond for unknown reasons. To reveal changes in 4-1BB–based CD19 CAR-T cells and identify biomarkers of response, we used single-cell RNA sequencing and protein surface marker profiling of patient CAR-T cells pre- and postinfusion into patients with NHL. At the transcriptional and protein levels, we note the evolution of CAR-T cells toward a nonproliferative, highly differentiated, and exhausted state, with an enriched exhaustion profile in CAR-T cells of patients with poor response marked by TIGIT expression. Utilizing in vitro and in vivo studies, we demonstrate that TIGIT blockade alone improves the antitumor function of CAR-T cells. Altogether, we provide evidence of CAR-T cell dysfunction marked by TIGIT expression driving a poor response in patients with NHL. Significance: This is the first study investigating the mechanisms linked to CAR-T patient responses based on the sequential analysis of manufactured and infused CAR-T cells using single-cell RNA and protein expression data. Furthermore, our findings are the first to demonstrate an improvement of CAR-T cell efficacy with TIGIT inhibition alone. This article is highlighted in the In This Issue feature, p. 1825
Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4
Pinsker, Jordan E. , Dassau, Eyal , Deshpande, Sunil , Raghinaru, Dan, Buckingham, Bruce A. , Kudva, Yogish C. , Laffel, Lori M. , Church, Mei Mei , Desrochers, Hannah, Ekhlaspour, Laya , Kaur, Ravinder Jeet , Levister, Camilla, Lum, John W. , Kollman, Craig, Ambler-Osborn, Louise, Freiner, Emily , O’Malley, Grenye , Brooks, Danielle , Ogyaadu, Selassie, Plesser, Mitchell, Simha, Vinaya , Desjardins, Donna, McCrady-Spitzer, Shelly , Nolander, Lisa, Hsu, Liana, Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Ekhlaspour, Laya , Lum, John , Doyle, Francis J , Buckingham, Bruce , Levy, Carol J. , Shi, Dawei , Kollman, Craig , Doyle, Francis J. , Isganaitis, Elvira , Beck, Roy W. , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | May 12, 2022 | Volume: 24 | Issue: 9 | Pages: 635-642

10.1089/dia.2022.0084 | PMID 35549708 Get It

Background: Automated insulin delivery (AID) systems have proven effective in increasing time-in-range during both clinical trials and real-world use. Further improvements in outcomes for single-hormone (insulin only) AID may be limited by suboptimal insulin delivery settings. Methods: Adults (≥18 years of age) with type 1 diabetes were randomized to either sensor-augmented pump (SAP) (inclusive of predictive low-glucose suspend) or adaptive zone model predictive control AID for 13 weeks, then crossed over to the other arm. Each week, the AID insulin delivery settings were sequentially and automatically updated by an adaptation system running on the study phone. Primary outcome was sensor glucose time-in-range 70–180 mg/dL, with noninferiority in percent time below 54 mg/dL as a hierarchical outcome. Results: Thirty-five participants completed the trial (mean age 39 ± 16 years, HbA1c at enrollment 6.9% ± 1.0%). Mean time-in-range 70–180 mg/dL was 66% with SAP versus 69% with AID (mean adjusted difference +2% [95% confidence interval: −1% to +6%], P = 0.22). Median time <70 mg/dL improved from 3.0% with SAP to 1.6% with AID (−1.5% [−2.4% to −0.5%], P = 0.002). The adaptation system decreased initial basal rates by a median of 4% (−8%, 16%) and increased initial carbohydrate ratios by a median of 45% (32%, 59%) after 13 weeks. Conclusions: Automated adaptation of insulin delivery settings with AID use did not significantly improve time-in-range in this very well-controlled population. Additional study and further refinement of the adaptation system are needed, especially in populations with differing degrees of baseline glycemic control, who may show larger benefits from adaptation.
Spinal Intervertebral Disc Regeneration Versus Repair: Cost, Outcomes and Future Considerations
Jarrah, Ryan , Reardon, Taylor , Warner, Tyler , Stefano, Frank A. De , Fiani, Brian , Stefano, Frank De

Mayo Clinic

Regenerative Medicine | May 12, 2022 | Volume: 17 | Issue: 6 | Pages: 337-340

10.2217/rme-2022-0049 | PMID 35545959 Get It

Urgent and emergent breast lesions – A primer for the general radiologist, on‐call resident and sonographer
Bhatt, Asha A. , Woodard, Genevieve A. , Lee, Christine U. , Hesley, Gina K.

Mayo Clinic

Australasian Journal of Ultrasound in Medicine | May 12, 2022 | Volume: 25 | Issue: 2 | Pages: 54-65

10.1002/ajum.12296 | PMID 35722051 Get It

AbstractThere are very few true breast emergencies. While infrequent, women do present to emergency departments or urgent care centres with breast‐related concerns. In this case‐based review, both common and uncommon urgent and emergent breast lesions are presented, emphasising ultrasound characteristics and imaging optimisation to improve accurate diagnosis and appropriate recommendations.
The Cytoskeleton Differentially Localizes the Early Growth Response Gene-1 Protein in Cancer and Benign Cells of the Prostate
Mora, Gloria R., Olivier, Kenneth R. , Cheville, John C. , Mitchell, Richard F., Lingle, Wilma L., Tindall, Donald J.

Mayo Clinic

Molecular Cancer Research | May 12, 2022 | Volume: 2 | Issue: 2 | Pages: 115-128

10.1158/1541-7786.115.2.2 Get It

Abstract Prostate cancer is the most prevalent malignancy and the second leading cause of cancer mortality in men. Early growth response gene-1 (EGR-1) plays a crucial role in the development and progression of prostate cancer. The presented data show that EGR-1 differs in cellular localization in benign cells compared with malignant prostate cells and that this localization is critical for the transcriptional activation of EGR-1-dependent genes. Immunohistochemistry of human prostate cancer specimens demonstrated higher levels of EGR-1 in malignant cells located predominantly in the cytoplasm, whereas benign cells contained lower levels of EGR-1 located predominantly in the nucleus. Benign prostate cells responded to mitogens in vitro, with increased levels of EGR-1, rapid nuclear translocation, and enhanced transcriptional activity, whereas malignant prostate cells did not exhibit the same responses, and the protein remained in the cytoplasm. The central aspect of this difference is the association of EGR-1 with microtubules, which is exclusive to the benign cells of the prostate and is requisite for the nuclear translocation and transcriptional activity of EGR-1. Our in vitro data demonstrate that the differences in EGR-1 between benign and malignant prostate cells extend beyond cellular levels, which was confirmed by immunohistochemistry in human tissues. Thus, we add the novel concept that microtubules regulate EGR-1 localization in benign prostate cells but not in malignant prostate cells.
COVID‐19‐associated secondary hemophagocytic lymphohistiocytosis requiring hematopoietic cell transplant
Greenmyer, Jacob R. , Wyatt, Kirk D. , Milanovich, Sam, Kohorst, Mira A. , Ferdjallah, Asmaa

Mayo Clinic

eJHaem | May 12, 2022 | Volume: 3 | Issue: 3 | Pages: 1025-1028

10.1002/jha2.456 | PMID 35941881 Get It

AbstractCoronavirus disease 2019 (COVID‐19) infection causes a variety of extrapulmonary complications in pediatric patients. Multisystem inflammatory syndrome and hemophagocytic lymphohistiocytosis (HLH) are related to hypercytokinemia in COVID‐19 patients. HLH is a disorder of exaggerated inflammation resulting in a cytokine storm and unrestricted hemophagocytosis. HLH can be primary (familial) or secondary (acquired). Secondary HLH (sHLH) can occur in patients with rheumatologic, oncologic, or infectious diseases. The link between COVID‐19 and HLH has been reported in pediatric patients. Here we report a case of a pediatric patient who developed refractory sHLH secondary to COVID‐19 infection and required a hematopoietic cell transplant for the cure.
Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer
Basu, Gargi D. , Pathangey, Latha , Tinder, Teresa L., LaGioia, Michelle, Gendler, Sandra , Mukherjee, Pinku

Mayo Clinic

Molecular Cancer Research | May 12, 2022 | Volume: 2 | Issue: 11 | Pages: 632-642

10.1158/1541-7786.632.2.11 Get It

Abstract Cyclooxygenase-2 (COX-2) inhibitors are rapidly emerging as a new generation of therapeutic drug in combination with chemotherapy or radiation therapy for the treatment of cancer. The mechanisms underlying its antitumor effects are not fully understood and more thorough preclinical trials are needed to determine if COX-2 inhibition represents a useful approach for prevention and/or treatment of breast cancer. The purpose of this study was to evaluate the growth inhibitory mechanism of a highly selective COX-2 inhibitor, celecoxib, in an in vivo oncogenic mouse model of spontaneous breast cancer that resembles human disease. The oncogenic mice carry the polyoma middle T antigen driven by the mouse mammary tumor virus promoter and develop primary adenocarcinomas of the breast. Results show that oral administration of celecoxib caused significant reduction in mammary tumor burden associated with increased tumor cell apoptosis and decreased proliferation in vivo. In vivo apoptosis correlated with significant decrease in activation of protein kinase B/Akt, a cell survival signaling kinase, with increased expression of the proapoptotic protein Bax and decreased expression of the antiapoptotic protein Bcl-2. In addition, celecoxib treatment reduced levels of proangiogenic factor (vascular endothelial growth factor), suggesting a role of celecoxib in suppression of angiogenesis in this model. Results from these preclinical studies will form the basis for assessing the feasibility of celecoxib therapy alone or in combination with conventional therapies for treatment and/or prevention of breast cancer.
Fatty acid synthase: a druggable driver of breast cancer brain metastasis
Menéndez, Javier A. , Lupu, Ruth , Menendez, Javier A

Mayo Clinic

Expert Opinion on Therapeutic Targets | May 12, 2022 | Volume: 26 | Issue: 5 | Pages: 427-444

10.1080/14728222.2022.2077189 | PMID 35545806 Get It

Advances in Primary Progressive Aphasia
Matías‐Guiu, Jordi A. , Lavoie, Monica , Utianski, Rene L. , Lavoie, Monica , Utianski, Rene L , Laforce, Robert

Mayo Clinic

Brain Sciences | May 12, 2022 | Volume: 12 | Issue: 5 | Pages: 636

10.3390/brainsci12050636 | PMID 35625022 Get It

Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by progressive and predominant language impairment [...]
Doctor, What Is the Best Crohn's Therapy?
Kane, Sunanda V. , Isaacs, Kim L.

Mayo Clinic

American Journal of Gastroenterology | May 12, 2022 | Volume: 117 | Issue: 7 | Pages: 1041-1043

10.14309/ajg.0000000000001832 | PMID 35546257 Get It

Abstract When the only biologics were antitumor necrosis factor agents, it was not hard to treat our sick Crohn's patients. Now with multiple mechanisms of action, the therapeutic landscape is more broad but can be confusing. Trying to compare agents is difficult because head-to-head trials are lacking. A comparative effectiveness methodology allows for indirect comparisons of agents based on the outcome of interest. When deciding what agent is “best” for any specific patient, multiple factors have to be taken into consideration including the primary outcome of interest. In this study, the outcome of mucosal healing is considered.